Lenvatinib HCC Results Give Sorafenib Cause To REFLECT?
Executive Summary
New comparative data released at ASCO reveal the scope of benefit for Eisai's lenvatinib over close competitor sorafenib in the first-line treatment of unresectable hepatocellular carcinoma. But the Eisai drug may face challenges in carving a position in this setting.
You may also be interested in...
Keeping Track: A Long-Awaited Approval For Generic EpiPen, Cancer Product Labels Expand And Constrict
The latest drug development news and highlights from our US FDA Performance Tracker.
Liver Cancer: What's Close To The Market
The treatment of liver cancer will have a makeover in coming months, with several products including Bristol’s Opdivo nearing the market for a disease that is often diagnosed late and where previously there have been few meaningful advances in therapy for many years. Two recently published reports from Datamonitor Healthcare have reviewed the disease and the R&D pipeline for the condition.
Quick Listen: Scrip's Five Must-Know Things
In this week's podcast version of Five Must-Know Things: planned US drug pricing legislation in focus; solid quarter but no Seagen announcement for Merck & Co; AbbVie’s Gonzalez sounds alarm over US pricing legislation; Alnylam ready to expand in amyloidosis; and Boehringer Ingelheim on global Jardiance strategy.